Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eight years ago, I wrote about a startup trying to deliver cancer ...

Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse.

Patients and prescribers alike are familiar with the vast array of psychiatric medicines available to treat mental illnesses. They are often less aware that certain psychotropics can be delivered via ...

Nutriband’s abuse-deterrent platform technology is now patented in 46 countries and territories covering major global markets. Nutriband (NTRB) is targeting to file for FDA approval for AVERSA™ ...

This review highlights the potential of natural polysaccharide microneedles in cancer immunotherapy, focusing on localized ...

Release liners are a key component in medical products’ overall development and performance, for example, transdermal drug delivery systems, medical devices, advanced wound care dressings and ...

Issuance of a new patent strengthens Nutriband's intellectual property protection for its AVERSA™ transdermal abuse deterrent technology in the United States. The technology potentially addresses ...

ORLANDO, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it ...

ORLANDO, FL / ACCESSWIRE / March 4, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that ...